#Canada #Aurora Cannabis #Edmonton #Copeia #Physician Experience Platform

Aurora and Copeia Unveil English Physician Experience Platform (PEP)

On September 9, 2025, Aurora Cannabis Inc., a leading global player in the medical cannabis industry, announced the launch of the English version of the Physician Experience Platform (PEP) in collaboration with Copeia, a German healthcare technology innovator. This new platform is set to enhance access for healthcare professionals to crucial peer-reviewed medical insights on the usage of cannabis in patient care.

Enhancing Physician Education

The development of the English PEP is regarded as a pivotal advancement in the education of healthcare providers about medical cannabis. As highlighted by Dr. Stephanie Lunn, Director of Medical Patient Affairs at Aurora, this platform aims to set a new benchmark in sharing clinical knowledge, which indirectly supports physicians' prescribing practices for medical cannabis. In her words, "By opening access to a broader audience of healthcare professionals, we're setting a new standard in peer-led clinical knowledge sharing that we believe will have a direct impact on the prescribing of medical cannabis."

The platform follows the successful launch of its German counterpart in early 2024, which already houses over 130 anonymized case studies from physicians using medical cannabis. This wealth of information will include data about patient histories, treatment outcomes, dosage instructions, and other relevant details which will assist healthcare providers in better understanding the therapeutic applications of cannabis.

Addressing Challenges in Prescribing

Garvin Hirt, CEO of Copeia, emphasized the hurdles physicians face when prescribing medical cannabis due to limited integration into conventional healthcare education systems. The new PEP platform aims to mitigate this issue by providing real-world data that can enhance personalized care.

"Physicians have long faced challenges prescribing medical cannabis - even when it may be the best option for a patient - due to its limited integration into established healthcare education and processes. Uncertainty and skepticism remain, underscoring the need for real-world data to enable personalized care and informed prescribing," said Hirt. The PEP will enable clinicians to search through the case reports in a comprehensive database, making firsthand experiences readily available.

Who Will Access the Platform?

Initially, physicians from Canada, the United Kingdom, Poland, Malta, the Czech Republic, Australia, and New Zealand will have access to this platform. To ensure the integrity of the information being shared, access to the PEP is gated by DocCheck login credentials, which are restricted to properly verified healthcare professionals.

While the English-language version will be initially read-only, plans are underway for a future iteration that would allow physicians to upload their case studies, potentially transforming it into an extensive international database of medical cannabis research. This collaborative approach may enhance global knowledge sharing and improve clinical practices across borders.

Future Prospects

The launch of the English PEP marks not just an essential step towards improving healthcare professionals' access to medical cannabis insights but also symbolizes a broader move towards integrating cannabis therapies into mainstream medical practices. As Aurora continues to break new ground in the medical cannabis sector, with a focus on science and innovation, it aims to promote better health outcomes for patients globally.

Healthcare providers interested in exploring the PEP platform can visit Copeia's website for the English version, while the German version is available at this link. Both platforms hold the potential to significantly impact the future of medical cannabis therapy.

About Aurora Cannabis Inc.

Headquartered in Edmonton, Alberta, Aurora Cannabis Inc. is a trailblazer in the global cannabis industry. The company caters to both medical and consumer markets, with a diverse brand portfolio that includes Drift, San Rafael '71, and MedReleaf. Aurora remains committed to improving lives through innovative cannabis solutions across various markets, fostering a future where cannabis is widely accepted and integrated into healthcare practices.

About Copeia

Founded in 2020, Copeia is a pioneering entity in medical informatics specializing in AI-driven solutions aimed at optimizing cannabis-based patient care. Having established itself in the German healthcare landscape, Copeia is making strides to expand its impact worldwide, empowering patients and healthcare professionals with robust, evidence-based resources for cannabis therapy.